Phytrax Lifesciences is building ASEAN’s first ICH Q7 & PIC/S-certified botanical API manufacturer at commercial scale — to turn tropical botanicals into pharmaceutical-grade active ingredients for regulated US, EU and ASEAN markets. Commissioning begins August 2026. This is the full investment story, told the way we’d walk you through it in the room.
If you only remember six things from the next thirty minutes, remember these. Each one is expanded in the chapters that follow.
Once commissioned, a regulatory position that takes 18–24 months of batch history to replicate — a head start we secure by building first.
The Series A commissions the plant and carries it to first commercial batches within ~18 months; letters of intent from pharmaceutical customers already in hand.
Southeast Asia grows the botanicals; the world lacks GMP capacity to convert them. We sit on both sides of that gap.
High-margin bulk API export plus Thai-registered finished dose — downstream margin with zero added CAPEX.
BOI Zone 3 promotion exempts corporate income tax on promoted activity through the growth phase.
The ICH Q7 sub-segment grows 14–16% CAGR as regulators displace non-compliant suppliers worldwide.
Southeast Asia is the source of the most commercially significant medicinal botanicals on earth. But turning a plant into a pharmaceutical-grade active ingredient requires ICH Q7 GMP manufacturing — and that capacity sits an ocean away, in India and China, under quality systems that Western regulators increasingly reject.
The biomass is here. The GMP capacity isn’t. Raw material is shipped thousands of miles to be processed, adding cost, carbon and supply-chain fragility to every gram of API.
FDA and EMA are intensifying API GMP inspections. Non-compliant suppliers are being displaced from regulated markets — but there is nowhere compliant to move the botanical volume to.
Pharmaceutical companies relying on botanical APIs have no PIC/S-certified source at the botanical origin. Their supply is single-threaded through geographies and quality systems they cannot audit to Western standards.
The structural opportunity in one sentence: whoever closes the gap between where botanicals grow and where GMP can convert them — first, and to Western regulatory standard — captures a defensible position in a $10.5 billion market. That is exactly what Phytrax is being built to do.
The global botanical API market grows 8–10% a year. The ICH Q7-compliant slice — the only tier a US, EU or Japanese drugmaker can actually buy from — is $2.1B and compounding at 14–16% as regulators tighten API standards worldwide. Phytrax plays exclusively there.
Global botanical API market, all quality tiers · 8–10% CAGR
ICH Q7-compliant segment — the only tier reachable in regulated US/EU/JP markets · 14–16% CAGR
Phytrax reachable revenue by 2031 on planned capacity + pipeline
We are vertically integrated by design across the whole chain: contract farming, GMP extraction and alkaloid isolation, and Thai-registered finished dose. That means we capture margin at every layer and sell into two markets at once — high-value bulk API to the world, and finished medicines at home.
Contract farming of 200 rai of Crinum viviparum secures raw material at the source.
GMP extraction and 300 mm prep-HPLC will deliver USP-grade crystalline alkaloids.
ISO 7 cleanrooms and DMF-backed release for US, EU and ASEAN customers.
Thai FDA-registered tablets via validated CMOs — downstream margin, no new CAPEX.
A focused portfolio of high-value alkaloids and finished doses — each tied to a real therapeutic market.
| Product | Therapeutic use | Regulatory status | Stream |
|---|---|---|---|
| Galantamine HBr USP | Alzheimer’s disease | US DMF planned · lead molecule | Bulk API |
| Mitragynine 95% | Analgesic research / reference | Launch molecule | Bulk API |
| Nuciferine 98% | Metabolic / reference standard | Launch molecule | Bulk API |
| Colchicine USP | Gout / anti-inflammatory | Second-wave molecule | Bulk API |
| Galantamine 8 mg tablet | Finished dose | Thai FDA registration planned (via CMO) | Finished dose |
| Colchicine 0.5 mg tablet | Finished dose | Pipeline | Finished dose |
The site, the promotion, the raw-material base and the team are locked in before a dollar of the raise is spent. What remains is commissioning and certification — a known, sequenced path, not open research.
Every batch will be released against USP monographs with validated methods — the paper trail regulated customers require, designed into the plant from day one.
Unlike a patent, none of these run out. They compound: every new batch extends the track record, every new customer reference deepens the switching cost.
PIC/S certification requires 18–24 months of commercial batch history, validated equipment and a documented quality track record from commissioning. By starting now, Phytrax banks that timeline first — and no new ASEAN entrant can compress it. The wall stands whether or not a competitor has the capital.
Once a customer references a Phytrax US FDA Type II DMF or ASMF in a drug filing, they take on a regulatory dependency on us. Changing supplier post-approval means comparability studies and filing amendments — so each new reference deepens the moat rather than diluting it.
Southeast Asia is the geographic source of the most valuable botanical raw materials, yet the GMP capacity to convert them sits elsewhere. Phytrax is being built to be the first PIC/S-certified botanical API manufacturer in ASEAN at commercial scale — closing that mismatch first.
From 200 rai of contract Crinum viviparum cultivation, through GMP API manufacture, to Thai FDA-registered finished tablets — margin is captured at every layer and supply is de-risked for internal and external customers alike, by design.
Operating from Bangkadi Industrial Park in Pathum Thani, a Board of Investment Zone 3 location, Phytrax qualifies for an 8-year corporate income tax exemption on promoted activity — a material after-tax cash advantage precisely during the growth phase.
Preparative HPLC at 300 mm bore, validated cleaning for multi-product shared equipment, and proprietary parameters for converting tropical biomass into USP-grade crystalline API — process knowledge that is hard to replicate without experienced pharmaceutical scientists.
Bulk API export is the engine: high-margin, USD-denominated and locked in through pharmaceutical supply agreements. Finished dose is the multiplier: it captures downstream margin from the same molecules with no additional CAPEX.
Ex-works gross margin, before logistics and regulatory cost. Recurring, contract-driven, USD-denominated.
Captured via validated Thai CMO partners — downstream margin with zero additional CAPEX.
Revenue is designed around multi-year pharmaceutical supply agreements, not one-off sales.
Once a customer references our DMF, changing supplier means refiling — so revenue is sticky by design.
BOI exemption means after-tax margins during the growth phase are materially higher than headline rates suggest.
The trajectory below is built bottom-up from customer LOIs and a costed commissioning plan, not top-down from market size. First revenue follows commissioning; bulk API leads, finished dose follows.
The Series A commissions the plant and carries it to first commercial batches — a costed, milestone-based plan.
The Series A funds the capacity that carries revenue through the cash trough to operating breakeven.
BOI CIT exemption means growth-phase cash is retained, not taxed — stretching every dollar raised.
The Series A funds the launch. Commissioning begins August 2026 — every milestone below is ahead of us, on a costed, sequenced plan.
Series A close; Bangkadi Industrial Park facility fit-out and commissioning; IQ/OQ/PQ initiated; contract-farming agreements executed for Crinum viviparum (Chachoengsao, 200 rai).
First engineering and validation batches of Mitragynine 95% and Nuciferine 98%; Thai FDA API Manufacturing Licence application; environmental monitoring programme established.
PIC/S-aligned inspection; US FDA Type II DMF filed for Galantamine HBr USP; MHRA site audit; first Galantamine HBr commercial batch released.
First export shipments to EU and US customers; Thai FDA registration of Galantamine 8 mg tablets via CMO; first pharmaceutical customers referencing Phytrax DMFs.
Second prep-HPLC train commissioned; Colchicine USP and precursor pipeline intake; ASEAN customer expansion across Malaysia, Vietnam and Indonesia.
Contract extraction services opened to external clients; target of three CDMO partnerships; potential pre-IPO raise or strategic pharmaceutical partner.
This is a regulated manufacturing business. It is run by people who have released batches, passed inspections and filed DMFs. Full bios and CVs are provided in the data room after NDA.
Sets strategy and owns capital, customer and regulatory relationships. Pharmaceutical operating background across API manufacturing and commercial supply.
Owns the ICH Q7 / PIC/S quality system and the DMF portfolio. Accountable for every inspection, filing and batch release.
Runs prep-HPLC isolation, cleanroom operations and process validation from biomass intake to crystalline API.
Owns the BOI relationship, financial controls, unit economics and the capital plan through Series A and beyond.
Manages contract-farming partnerships and the 200-rai cultivation base underpinning raw-material security.
Phytochemistry and analytical experts guiding molecule selection, method development and the new-molecule pipeline.
Phytrax Lifesciences Co., Ltd. is a Thai BOI-promoted company operating from Bangkadi Industrial Park, Zone 3.
A PIC/S-aligned quality management system sits at the centre of the org — independent of commercial pressure.
Post-Series A the board expands to include investor representation and independent pharma governance.
The site is secured, the demand is real and the plan is costed. This round funds commissioning, certification, the pipeline and the working capital to reach commercial revenue — through the cash trough to operating breakeven.
Valuation, detailed terms and full financials are shared under NDA. Figures indicative and subject to definitive documentation.
We welcome enquiries from institutional investors, strategic pharmaceutical partners, family offices and qualified individuals from a US $500K commitment. Every enquiry is confidential; an NDA precedes any non-public financials.
Investment risk disclosure: Investment in an early-stage pharmaceutical manufacturer carries significant risk, including total loss. Projections are illustrative and not a guarantee of future performance. Past certifications do not guarantee continued compliance. This page is not a securities offering or investment advice. Consult qualified financial and legal advisors before investing.